المؤلفون: N. P. Knyazheskaya, E. Кh. Anaev, A. S. Belevskiy, M. A. Makarova, Н. П. Княжеская, Э. Х. Анаев, А. С. Белевский, М. А. Макарова

المصدر: Meditsinskiy sovet = Medical Council; № 18 (2022); 49-54 ; Медицинский Совет; № 18 (2022); 49-54 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: вилантерол/умеклидиний, LABA, long-acting β2-agonists, LAMA, long-acting anticholinergic drugs, double bronhodilatation, vilanterol/umeclidinium, длительно действующие β2 -агонисты, длительно действующие антихолинергические препараты, двойная бронходилатация

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7119/6391Test; Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20Test.; GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. https://doi.org/10.1016/S0140-6736Test(14)61682-2.; Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. https://doi.org/10.1183/09031936.06.00025805Test.; Shin S., Bai L., Burnett R.T., Kwong J.C., Hystad P., van Donkelaar A. et al. Air Pollution as a Risk Factor for Incident Chronic Obstructive Pulmonary Disease and Asthma. A 15-Year Population-based Cohort Study. Am J Respir Crit Care Med. 2021;203(9):1138–1148. https://doi.org/10.1164/rccm.201909-1744OCTest; Wang H.H., Cheng S.L. From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease. Biomedicines. 2021;9(11):1638. https://doi.org/10.3390/biomedicines9111638Test.; Caramori G., Casolari P., Barczyk A., Durham A.L., Di Stefano A., Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38(4):497–515. https://doi.org/10.1007/s00281-016-0561-5Test.; Yang W., Li F., Li C., Meng J., Wang Y. Focus on Early COPD: Definition and Early Lung Development. Int J Chron Obstruct Pulmon Dis. 2021;16:3217–3228. https://doi.org/10.2147/COPD.S338359Test.; Barr R.G., Bluemke D.A., Ahmed F.S., Carr J.J., Enright P.L., Hoffman E.A. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227. https://doi.org/10.1056/nejmoa0808836Test.; Agusti A., MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68(7):687–690. https://doi.org/10.1136/thoraxjnl-2012-202772Test.; Soler-Cataluña J.J., Alcázar-Navarrete B., Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397–1405. https://doi.org/10.2147/COPD.S71370Test.; Soler-Cataluña J.J., Marzo M., Catalán P., Miralles C., Alcazar B., Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719–3731. https://doi.org/10.2147/COPD.S178149Test.; Miravitlles M., Alcázar B., Soler-Cataluña J.J. The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. Pulmonologiya. 2020;30(2):135–141. https://doi.org/10.18093/0869-0189-2020-30-2-135-141Test.; Авдеев С.Н., Невзорова В.А., Куделя Л.М., Кондрашова Н.М., Суханова Г.И., Киняйкин М.Ф. и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019;29(3):365–374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374Test.; Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительной терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;(3):24–32. Режим доступа: https://www.elibrary.ru/item.asp?id=25402705Test.; Williams D.M., Rubin B.K. Clinical Pharmacology of Bronchodilator Medications. Respir Care. 2018;63(6):641–654. https://doi.org/10.4187/respcare.06051Test.; Kruse A.C., Li J., Hu J., Kobilka B.K., Wess J. Novel insights into M3 muscarinic acetylcholine receptor physiology and structure. J Mol Neurosci. 2014;53(3):316–323. https://doi.org/10.1007/s12031-013-0127-0Test.; Miravitlles M., Baek S., Vithlani V., Lad R. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same? Tuberc Respir Dis (Seoul). 2018;81(3):198–215. https://doi.org/10.4046/trd.2018.0040Test.; Maqsood U., Ho T.N., Palmer K., Eccles F.J., Munavvar M., Wang R. et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):CD012930. https://doi.org/10.1002/14651858.cd012930.pub2Test.; Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149(5):1181–1196. https://doi.org/10.1016/j.chest.2016.02.646Test.; Meurs H., Dekkers B.G., Maarsingh H., Halayko A.J., Zaagsma J., Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145–155. https://doi.org/10.1016/j.pupt.2012.07.003Test.; Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. https://doi.org/10.1016/j.pupt.2010.03.003Test.; Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. https://doi.org/10.1016/S2213-2600Test(14)70065-7; Larsson K., Ekberg-Jansson A., Stridsman C., Hanno M., Vanfleteren L.E.G.W. Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease – Results from the Swedish National Airway Register. Int J Chron Obstruct Pulmon Dis. 2021;16:909–918. https://doi.org/10.2147/copd.s300299Test.; Колонтарева Ю.М., Барабанова Е.Н. Комбинированные бронхолитики в терапии ХОБЛ. Лечащий врач. 2016;(12):85–90. Режим доступа: https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698Test.; Procopiou P.A., Barrett V.J., Bevan N.J., Biggadike K., Box P.C., Butchers P.R. et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522–4530. https://doi.org/10.1021/jm100326dTest.; Burkes R.M., Panos R.J. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020;12:589–602. https://doi.org/10.2147/jep.s259328Test.; Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L. et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. https://doi.org/10.1378/chest.11-2231Test.; Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–1208. https://doi.org/10.2147/dddt.s39449Test.; Celli B., Crater G., Kilbride S., Mehta R., Tabberer M., Kalberg C.J., Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. https://doi.org/10.1378/chest.13-1579Test.; Donohue J.F., Maleki-Yazdi M.R., Kilbride S., Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. https://doi.org/10.1016/j.rmed.2013.06.001Test.; Maleki-Yazdi M.R., Kaelin T., Richard N., Zvarich M., Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. https://doi.org/10.1016/j.rmed.2014.10.002Test.; Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(11):2518–2533. https://doi.org/10.1007/s12325-017-0626-4Test.; Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. https://doi.org/10.1136/thorax.57.10.847Test.; Makris D., Moschandreas J., Damianaki A., Ntaoukakis E., Siafakas N.M., Milic Emili J., Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101(6):1305–1312.; Kerkhof M., Voorham J., Dorinsky P., Cabrera C., Darken P., Kocks J.W.H. et al. The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. Int J Chron Obstruct Pulmon Dis. 2020;15:1909–1918. https://doi.org/10.2147/copd.s253812Test.; Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. https://doi.org/10.1183/09031936.00111707Test.; Jones P.W. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. https://doi.org/10.1081/copd-200050513Test.; Donohue J.F. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. https://doi.org/10.1081/copd-200053377Test.; Westwood M., Bourbeau J., Jones P.W., Cerulli A., Capkun-Niggli G., Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12(1):40. https://doi.org/10.1186/1465-9921-12-40Test.; Singh D., Maleki-Yazdi M.R., Tombs L., Iqbal A., Fahy W.A., Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. https://doi.org/10.2147/copd.s101612Test.; https://www.med-sovet.pro/jour/article/view/7119Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-18-49-54Test
https://doi.org/10.18093/0869-0189-2017-27-1-13-20Test
https://doi.org/10.1016/S0140-6736Test(14)61682-2
https://doi.org/10.1183/09031936.06.00025805Test
https://doi.org/10.1164/rccm.201909-1744OCTest
https://doi.org/10.3390/biomedicines9111638Test
https://doi.org/10.1007/s00281-016-0561-5Test
https://doi.org/10.2147/COPD.S338359Test
https://doi.org/10.1056/nejmoa0808836Test
https://doi.org/10.1136/thoraxjnl-2012-202772Test

المؤلفون: I. Demko V., N. Gordeeva V., A. Kraposhina Yu., M. Mamaeva G., I. Soloveva A., И. Демко В., Н. Гордеева В., А. Крапошина Ю., М. Мамаева Г., И. Соловьева А.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2020); 90-95 ; Медицинский Совет; № 21 (2020); 90-95 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: chronic obstructive pulmonary disease, bronchodilators, long acting beta agonists, long acting muscarinic antagonists, Vilanterol, Umeclidinium, olodaterol, Tiotropium bromide, хроническая обструктивная болезнь легких, бронходилататоры, длительнодействующий антихолинергический препарат, длительнодействующий β2-агонист, вилантерол, умеклидиний, олодатерол, тиотропия бромид

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/5970/5450Test; Кулик Е.Г., Павленко В.И., Нарышкина С.В. Вероятностная оценка обострений у больных ХОБЛ категории низкого риска на фоне долгосрочного лечения рофлумиластом. Амурский медицинский журнал. 2019;(3):19–22. Режим доступа: https://elibrary.ru/item.asp?id=41440324Test.; Зырянов С.К., Галатонова Ю.А. Клиническая и фармакоэкономическая оценка применения комбинации тиотропия бромида и олодатерола у пациентов с хронической обструктивной болезнью легких. Медицинский совет. 2018;(6):61–65. doi:10.21518/2079-701X-2018-6-61-65.; Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin B.V., Manakov L.G., Antonini P. et al. Chronic respiratory pulmonary diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;9(1):963–974. doi:10.2147/COPD.S67283.; Демко И.В., Мамаева М.Г., Гордеева Н.В., Соловьева И.А., Крапошина А.Ю. Клинический опыт применения двойной бронходилатационной терапии у пациентов с ХОБЛ. Медицинский совет. 2019;(15):7–10. doi:10.21518/2079-701X-2019-15-7-10.; Романовских А.Г., Белоцерковская Ю.Г., Стырт Е.А. Современные подходы к фармакотерапии хронической обструктивной болезни легких: место фиксированных комбинированных препаратов. Клиническая медицина. 2015;93(12):38–43. Режим доступа: https://elibrary.ru/item.asp?id=25401657Test.; Авдеев С.Н., Айсанов З.Р., Белевский А.С., Визель А.А., Зырянов С.К., Игнатова Г.Л. и др. Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества. Пульмонология. 2017;27(1):108–113. doi:10.18093/0869-0189-2017-27-1-108-113.; Синопальников А.И. Фиксированные комбинации бронходилататоров в лечении больных ХОБЛ: проблема выбора. Медицинский совет. 2018;(15):96–100. doi:10.21518/2079-701X-2018-15-96-1006.; Riley C.M., Sciurba F.C. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA. 2019;321(8):786–797. doi:10.1001/jama.2019.0131.; Лещенко И.В. Фиксированные комбинации длительно действующих бронходилататоров при хронической обструктивной болезни легких: безопасность, эффективность и сердечно-сосудистая система. Медицинский совет. 2018;(15):18–26. doi:10.21518/2079-701X-2018-15-18-26.; Calzetta L., Matera, M.G., Cazzola M. Pharmacological interaction between LABAs and LAMAs in the respiratory tract: optimization of synergy. Eur J Pharmacol. 2015;(761):168–173. doi:10.1016/j.ejphar.2015.05.020.; Ferguson G.T., Flezar M., Korn S., Korducki L., Grönke L., Abrahams R., Buhl R. Efficacy of tio tropium+olodaterol in patients with chronic obstructive pul monary disease by initial disease severity and treatment inten sity: a post hoc analysis. Adv Ther. 2015;32(6):523–536. doi:10.1007/s12325-015-0218-0.; Beeh K.M., Westerman J., Kirsten A.M., Hébert J., Grönke L., Hamilton A. et al. The 24h lung function profile of once daily tiotropium and olodaterol fixed dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;(32):53–59. doi:10.1016/j.pupt.2015.04.002.; Игнатова Г.Л., Антонов В.Н. Небулайзерная терапия при заболеваниях легких. Медицинский совет. 2020;(11):102–106. doi:10.21518/2079-701X-2020-11-102-106.; Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi:10.1016/j.pupt.2010.03.003.; Визель А.А., Визель И.Ю., Бакунина Е.А. Хроническая обструктивная болезнь легких: современные подходы к терапии. Медицинский совет. 2016;(15):6–10. doi:10.21518/2079-701X-2016-15-6-10.; Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Сhest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.646.; Donohue J.F., Maleki-Yazdi M.R., Kilbride S, Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. Клинические рекомендации Российского респираторного общества: Алгоритм ведения больных ХОБЛ. Терапия. 2017;(4):102–106. Режим доступа: https://therapy-journal.ru/ru/archive/article/35046Test.; Свидерская Л.Н., Симакова В.М., Демко И.В., Хендогина В.Т., Кудрявцева А.Н., Третьяк Т.В. и др. Сравнительная оценка организации контроля доступности и качества оказания медицинской помощи в условиях краевой консультативной поликлиники. Сибирское медицинское обозрение. 2016;(5):53–64. Режим доступа: https://elibrary.ru/item.?id=27487911Test.; Singh D., Ferguson G.T., Bolitschek J., Grönke L., Hallmann C., Bennett N. et al. Tiotropium + olodaterol shows clinically meaningful improvements in qual ity of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002.; Трушенко Н.В., Сопова М.И., Сопова В.И. Фенотипы хронической обструктивной болезни легких – путь к персонифицированной терапии. Практическая пульмонология. 2019;(3):32–39. Режим доступа: https://elibrary.ru/item.asp?id=42211538Test.; Blair H.A., Deeks E.D. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75(1):61–74. doi:10.1007/s40265-014-0326-1.; Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(1):2518–2533. doi:10.1007/s12325-017-0626-4.; Calzetta L., Matera M.G., Cazzola M., Rogliani P. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. Adv Ther. 2019;36(12):3291–3298. doi:10.1007/s12325- 019-01119-w.; Толкушин А.Г., Погудина Н.Л. Фармакоэкономический анализ лекарственного лечения хронической обструктивной болезни легких: вилантерол + умеклидиния бромид по сравнению с другими комбинациями длительно действующих ß-агонистов и антихолинергетиков. Медицинские технологии. Оценка и выбор. 2018;(3):75–88. doi:10.31556/2219-0678.2018.33.3.075-088.; Зыков К.А., Овчаренко С.И. Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения. Медицинский совет. 2015;(17):24–31. doi:10.21518/2079-701X-2015-17-24-31.; Авдеев С.Н., Айсанов З.Р. Максимальная бронходилатация со старта терапии хронической обструктивной болезни легких: влияние на течение заболевания. Пульмонология. 2016;26(5):604–609. doi:10.18093/0869-0189-2016-26-5-604-609.; https://www.med-sovet.pro/jour/article/view/5970Test

الإتاحة: https://doi.org/10.21518/2079-701X-2020-21-90-95Test
https://doi.org/10.21518/2079-701X-2018-6-61-65Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.21518/2079-701X-2019-15-7-10Test
https://doi.org/10.18093/0869-0189-2017-27-1-108-113Test
https://doi.org/10.21518/2079-701X-2018-15-96-1006Test
https://doi.org/10.1001/jama.2019.0131Test
https://doi.org/10.21518/2079-701X-2018-15-18-26Test
https://doi.org/10.1016/j.ejphar.2015.05.020Test
https://doi.org/10.1007/s12325-015-0218-0Test

المؤلفون: A. A. Vizel', I. Yu. Vizel', А. А. Визель, И. Ю. Визель

المصدر: PULMONOLOGIYA; Том 28, № 1 (2018); 96-103 ; Пульмонология; Том 28, № 1 (2018); 96-103 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-1

مصطلحات موضوعية: олодатерол / тиотропий, dual bronchodilation, vilanterol/umeclidinium, olodaterol/tiotropium, двойная бронходилатация, вилантерол / умеклидиний

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/966/809Test; Blanco I., Diego I., Bueno P. et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 13: 57–67. DOI:10.2147/COPD.S150853.; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report. © 2018 Global Initiative forChronic Obstructive Lung Disease, Inc. Available at: http://goldcopd.org/wp-content/uploads/2016/04/GOLD-2018-WMS.pdfTest; Feldman G.J., Sousa A.R., Lipson D.A. et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv. Ther. 2017; 34 (11): 2518–2533. DOI:10.1007/s12325-017-0626-4.; Российское респираторное общество. Обновленный проект клинических рекомендаций: Хроническая обструктивная болезнь легких. 2016. Доступно по: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsiiTest/ [Дата обращения 12.02.2018]. / Russian Respiratory Society. Updated Project of Clinical Guidelines: Chronic Obstructive Pulmonary Disease. 2016. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsiiTest/ (in Russian).; Rodrigo G.J., Price D., Anzueto A. et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 907–922. DOI:10.2147/COPD.S130482.; Wedzicha J.A., Zhong N., Ichinose M. et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 339–349. DOI:10.2147/COPD.S125058.; Calzetta L., Rogliani P., Matera M.G., Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016; 149 (5): 1181–1196. DOI:10.1016/j.chest.2016.02.646.; Schlueter M., Gonzalez-Rojas N., Baldwin M. et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther. Adv. Respir. Dis. 2016; 10 (2): 89–104. DOI:10.1177/1753465815624612.; Sion K.Y.J., Huisman E.L., PunekarIan Y. S. et al. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations in COPD. Pulm. Ther. 2017; 3: 297–316. DOI:10.1007/s41030-017-0048-0.; Calzetta L., Ora J., Cavalli F. et al. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis. Respir. Med. 2017; 129: 189–198. DOI:10.1016/j.rmed.2017.06.020.; Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI:10.1183/09031936.00200212.; Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45 (4): 969–979. DOI:10.1183/09031936.00136014.; Miravitlles M., Chapman K.R., Chuecos F. et al. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2041–2053. DOI:10.2147/COPD.S114566.; Kerwin E., Ferguson G.T., Sanjar S. et al. Dual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: Results from two randomized, controlled, cross-over studies. Lung. 2017; 195 (6): 739–747. DOI:10.1007/s00408-017-0055-9.; Donohue J.F. Minimal clinically important differences in COPD lung function. COPD; 2005; 2 (1): 111–124.; Cazzola M., MacNee W., Martinez F.J. et al. ATS/ERS Task Force. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–468. DOI:10.1183/09031936.00099306.; Jones P.W., Beeh K.M., Chapman K.R. et al. Minimal clinically important differences in pharmacological trials. Am. J. Respir. Crit. Care Med. 2014; 189 (3): 250–255. DOI:10.1164/rccm.201310-1863PP.; Chapman K.R., Beeh K.M., Beier J. et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med. 2014; 14: 4. DOI:10.1186/1471-2466-14-4.; Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int. J. COPD. 2016; 11 (1): 719–730. DOI:10.2147/COPD.S102494.; Agustí A., de Teresa L., De Backer W. et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur. Respir. J. 2014; 43 (3): 763–772. DOI:10.1183/09031936.00054213.; Ichinose M., Fujimoto T., Fukuchi Y. Tiotropium 5 μg microg via Respimat and 18 μg microg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir. Med. 2010; 104 (2): 228–236. DOI:10.1016/j.rmed.2009.11.011.; Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicines for Human Use. London, 27 July 2000. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdfTest; Westwood M., Bourbeau J., Jones P.W. et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir. Res. 2011; 12: 40. DOI:10.1186/1465-9921-12-40.; Zider A.D., Wang X., Buhr R.G. et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017; 152 (3): 494–501. DOI:10.1016/j.chest.2017.04.174.; Tashkin D.P., Rennard S.I., Martin P. et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68 (14): 1975–2000.; García-Río F., Soler-Cataluña J.J., Alcazar B. et al. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers' point of view: Results of the EPOCA Delphi consensus. COPD. 2017; 14 (6): 573–580. DOI:10.1080/15412555.2017.1365120.; Ciciliani A.M., Langguth P., Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1565–1577. DOI:10.2147/COPD.S115886.; Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J. 2017; 49: 1601794. DOI:10.1183/13993003.01794-2016.; van der Palen J., Thomas M., Chrystyn H. et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim. Care Respir. Med. 2016; 26: 16079. DOI:10.1038/npjpcrm.2016.79.; https://journal.pulmonology.ru/pulm/article/view/966Test

الإتاحة: https://doi.org/10.18093/0869-0189-2018-28-1-96-103Test
https://doi.org/10.18093/0869-0189-2018-28-1Test
https://doi.org/10.2147/COPD.S150853Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.1007/s12325-017-0626-4Test
https://doi.org/10.2147/COPD.S130482Test
https://doi.org/10.2147/COPD.S125058Test
https://doi.org/10.1016/j.chest.2016.02.646Test
https://doi.org/10.1177/1753465815624612Test
https://doi.org/10.1007/s41030-017-0048-0Test

المؤلفون: A. Sinopalnikov I., А. Синопальников И.

المصدر: Meditsinskiy sovet = Medical Council; № 15 (2018); 96-100 ; Медицинский Совет; № 15 (2018); 96-100 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-15

مصطلحات موضوعية: chronic obstructive pulmonary disease, fixed-dose combinations of LABA/LAAC, vilantherol/umeclidinium, хроническая обструктивная болезнь легких, фиксированные комбинации ДДБА/ДДХБ, вилантерол/умеклидиний

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/2677/2639Test; Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2018. Available from: http://goldcopd.org/gold-2018-global-strategy-diagnosis-management-prevention-copdTest/.; Lopez-Campos JL. Treatment strategies in chronic obstructive pulmonary disease: a proposal for standardization. Arch Bronconeumol, 2010, 46: 617-620.; Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol, 2017, 53: 324-335.; COPD: NICE guideline DRAFT (July 2018). Available from: http://www.nice.org.ukTest.; Aisanov Z, Avdeev S, Arkhipov V, et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J COPD, 2018, 13: 183-187.; Williams DM, Rubin BK. Clinical pharmacology of bronchodilator medications. Respir Care, 2018, 63: 641-654.; Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest, 2001, 120: 258-270.; Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy, 2004, 3: 271-277.; Bennett WD, Almond MA, Zeman KL, et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther, 2006, 19: 96-100.; Profita M, Giorgi RD, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy, 2005, 60: 1361-1369.; Cazzola M, Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23: 257-267.; Miravitlles M, Baek S, Vithlani V, Lad R. Optimal bronchodilation for COPD patients: are all long-acting β2-agonist/long-acting muscarinic antagonists the same? Tuberc Respir Dis, 2018, 81: 198-215.; Price D, Ǿstrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J COPD, 2017, 12: 141-168.; Rodrigo GJ, Price D, Anzueto A, et al. LABA/ LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J COPD, 2017, 12: 07-922.; Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive disease (COPD). Cochrane Database Syst Rev, 2017, 2: CD012066.; Miravitlles M, Anzueto A. A new two-step algorithm for the treatment of COPD. Eur Respir J, 2017, 49: 1602200.; Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv ther, 2017, 34: 2518-2533.; Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest, 2016, 149: 11811196.; Kerwin E, Ferguson GT, Sanjar S, et al. Dual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung, 2017, 195: 739-747.; Navarrete BA et al. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulm Ther, 2018, June 20.; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/astrazenecaprovides-update-on-aeristo-phase-iiib-trial-forbevespi-aerosphere-in-chronic-obstructive-pulmonary-disease23082018.htmlTest.; https://www.med-sovet.pro/jour/article/view/2677Test

الإتاحة: https://doi.org/10.21518/2079-701X-2018-15-96-100Test
https://doi.org/10.21518/2079-701X-2018-15Test
https://www.med-sovet.pro/jour/article/view/2677Test